Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.33 |
| ▸ | FDPS | P14324 | 5/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059577 | 0.72 | TSHR (0.52) | TSHRCYP2C19ANPEPERAP2 | |
| SCHEMBL9435851 | 0.71 | TSHR (0.41) | TSHRCYP2C19ANPEPERAP2 | |
| SCHEMBL11184988 | 0.70 | TSHR (0.32) | TSHRCYP2C19 | |
| SCHEMBL8730256 | 0.67 | PTPN11 (0.33) | TSHRCYP2C19 | |
| Medronic Acid SCHEMBL730920 | 0.67 | TSHR (0.50) | TSHRCYP2C19ANPEPERAP2METAP1 | |
| SCHEMBL28065420 | 0.67 | MME (0.33) | TSHRCYP2C19 | |
| SCHEMBL8362551 | 0.66 | SLC6A4 (0.31) | — | |
| SCHEMBL1276569 | 0.64 | SLC6A4 (0.31) | — | |
| SCHEMBL5394737 | 0.64 | TSHR (0.50) | TSHRCYP2C19ANPEPERAP2 | |
| SCHEMBL9794973 | 0.64 | TSHR (0.46) | TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1077690-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | Neurochem, Inc. (CA) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059571-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | NEUROCHEM, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | TSHR 4800/4885CYP2C19 4749/4885ANPEP 751/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | TSHR 3280/4885CYP2C19 3798/4885ANPEP 161/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | TSHR 2787/4885CYP2C19 4108/4885ANPEP 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.